Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

Crosby, Jacqueline A.; Catton, Charles; Davis, Aileen M.; Couture, Jean; O’Sullivan, Brian; Kandel, Rita A.; Swallow, Carol J.

doi:10.1007/s10434-001-0050-4

Cited by 285 publications

(199 citation statements)

References 38 publications

(47 reference statements)

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Historically, the 5-year survival rate has been approximately 35%-65% among patients able to undergo complete resection. Among patients with unresectable disease, the median survival time is 10-20 months [6][7][8][9][10]. These observations suggest that microscopic disease often persists despite surgical resection of solid tumors.…”

Section: Case Studies In Gist Managementmentioning

confidence: 99%

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

et al. 2006

View full text Add to dashboard Cite

The introduction of imatinib, an orally administered inhibitor of the KIT receptor tyrosine kinase, is prompting revision of the management algorithms that have traditionally guided the treatment of gastrointestinal stromal tumor (GIST). Historically, patients with GISTs have had substantial rates of relapse as well as limited long-term survival even after complete surgical resection of a primary tumor. Imatinib has been shown to induce durable tumor responses in more than half of the patients with malignant metastatic or unresectable GISTs and to halt disease progression in an additional third. These encouraging results have led to the initiation of clinical trials of imatinib as an adjuvant or neoadjuvant therapy with surgery. Until relevant data are reported to provide definitive direction for the management of operable or potentially operable GISTs, treatment decisions must be made on the basis of the available evidence and clinical experience with imatinib. This paper presents selected case studies describing approaches to the combined use of surgery and systemic therapy that have been applied in the treatment of individual GIST patients. The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists. The Oncologist 2006;11:9-20

show abstract

Section: Case Studies In Gist Managementmentioning

confidence: 99%

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The prognosis of the digestive stromal tumours is difficult to assess. 13 The classical malignancy two predictive factors are the mitotic index and the tumour size; these factors allow us to distinguish between low risk malignancy, moderate risk malignancy and high risk malignancy stromal tumours. 14 The retrospective analysis of the recent series has confirmed these data, and has introduced another predictive factor: the tumour seat with a pejorative risk for the small bowel localization.…”

Section: Discussionmentioning

confidence: 99%

Small bowel stromal tumour revealed by a lower gastrointestinal bleeding

et al. 2016

View full text Add to dashboard Cite

“…Es un tumor radioresistente, además como otros sarcomas intraabdominales no pueden ser tratados con radioterapia por la importante morbilidad que se produciría al estar ubicados vecinos a otros órganos, que toleran limitadamente las dosis de radiación a administrar. Se han descrito tratamientos con radioterapia en GIST fijo a pared abdominal o irresecables fijos a otros órganos, pero con malos resultados 38 . La radioterapia no es un estándar de tratamiento adyuvante en GIST, podría tener algún rol en casos seleccionados como paliación.…”

Section: Factores Pronóstico Clínicos Y Patológicosunclassified

Tumores del estroma gastrointestinal (GIST), un particular tipo de neoplasia

2008

Rev. méd. Chile

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIS) are a heterogeneous group of tumors that express CD (Rev Méd Chile 2008; 136: 921-9L as primeras descripciones de tumores mesenquimáticos del tracto gastrointestinal datan de la década del 40 1 . Durante años fueron clasificados como tumores derivados de células musculares lisas basados en el parecido histológico con estas células, así fueron llamados leiomiomas bizarros, leiomiomas celulares y leiomiosarcomas 2 .Con el advenimiento de la microscopia electrónica se demostró que sólo algunos de estos tumores mostraban evidencias ultraestructurales de presentar diferenciación muscular lisa. La caracterización inmunohistoquímica ha permitido conocer los distintos tipos de diferenciación que presentan estos tumores. En 1984, Herrera et al 3 describieron una diferenciación neuronal autonó-mica en algunos subtipos de este tumor que desde 1983, gracias al trabajo de Manzur y Clark 4 , se habían denominado genéricamente como "tumores estromales". Pese a los avances, aun en la década de los 80 persistían las dudas dado que estos tumores poseen diferenciación miogénica, neural, pero también pueden presentar diferenciación mixta o sencillamente no presentar diferenciación específica. Otro hito en la historia de esta enfermedad lo marcó Hirota et al. que en 1998 descubre mutaciones funcionantes en el protooncogén c-kit de los GIST, lo que permitió a la larga una clasificación adecuada de los tumores, así como el desarrollo de una novedosa terapia molecular dirigida contra la tirosina kinasa 5 .Se ha sugerido que los GIST se originan de las células intersticiales de Cajal o desde células precursoras primitivas que se diferencian hacia

show abstract

Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

Cited by 285 publications

References 38 publications

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

Small bowel stromal tumour revealed by a lower gastrointestinal bleeding

Tumores del estroma gastrointestinal (GIST), un particular tipo de neoplasia

Contact Info

Product

Resources

About